Bristol Myers Squibb

Bristol Myers Squibb accounts for 24 tracked companies with verified cap-table data, 24 of which disclose round sizes totalling $3.5B. The median disclosed raise is $135M, and the largest is TORL BioTherapeutics at $450M, ahead of Metagenomi ($300M) and Asher Bio ($215M).

The names that recur most often on these portfolio cap tables are Bristol Myers Squibb (24 companies), Alexandria Venture Investments (7 companies), Leaps by Bayer (3 companies), GV (3 companies), Pfizer Ventures (3 companies), Deep Track Capital (2 companies). By latest disclosed round, the market skews Series B (12), Series A (8), Series C (4).

• Companies tracked: 24
• Disclosed funding total: $3.5B across 24 companies
• Median disclosed raise: $135M
• Largest raise: TORL BioTherapeutics — $450M
• Stage mix: Series B 12 · Series A 8 · Series C 4
• Most recent dated round: 2026-01-12

Best funded Bristol Myers Squibb companies

1. TORL BioTherapeutics — $450M (latest: Series C)
2. Metagenomi — $300M (latest: Series B)
3. Asher Bio — $215M (latest: Series C)
4. Nuvig Therapeutics — $208M (latest: Series B)
5. Attralus — $201M (latest: Series B)
6. ROME Therapeutics — $199M (latest: Series B)
7. Mediar Therapeutics — $181M (latest: Series A)
8. GlycoEra — $179M (latest: Series B)
9. Accent Therapeutics — $178M (latest: Series C)
10. Autobahn Therapeutics — $176M (latest: Series B)
11. Capstan Therapeutics — $165M (latest: Series A)
12. Cour Pharmaceuticals Development — $135M (latest: Series A)
13. Octant Bio — $115M (latest: Series B)
14. Orna Therapeutics — $100M (latest: Series A)
15. Cajal Neuroscience — $96M (latest: Series A)

Bristol Myers Squibb — related firms and companies (56)

• TORL BioTherapeutics
• Metagenomi
• Asher Bio
• Nuvig Therapeutics
• Attralus
• ROME Therapeutics
• Mediar Therapeutics
• GlycoEra
• Investors like Venrock
• Investors like First Round Capital
• Ceptur Therapeutics
• Investors like Atlas Venture
• Investors like Redpoint
• Octant Bio
• Investors like Floodgate
• Investors like Alumni Ventures
• Investors like QED Investors
• Sapience Therapeutics
• Investors like Canaan Partners
• Investors like Recursive Ventures
• Orna Therapeutics
• Investors like Mayfield Fund
• Investors like Ribbit Capital
• Investors like Accomplice
• Transition Bio
• Investors like Ridge Ventures
• Investors like FirstMark
• Cajal Neuroscience
• Investors like Salesforce Ventures
• Investors like Torch Capital
• Investors like Liquid 2 Ventures
• Prellis Biologics
• Investors like Western Technology Investment
• Investors like Foundation Capital
• Ratio Therapeutics
• Investors like ACME Capital
• Investors like Initialized Capital
• Accent Therapeutics
• NeoPhore
• Investors like Matrix
• Investors like White Star Capital
• Clade Therapeutics
• Investors like Upfront Ventures
• Investors like Zetta Venture Partners
• Autobahn Therapeutics
• Bristol Myers Squibb co-investors 2026
• Investors like Balderton Capital
• Investors like Peak XV Partners
• Precede Biosciences
• Investors like Bienville Capital
• Investors like Acre Venture Partners
• Capstan Therapeutics
• Investors like Bristol Myers Squibb
• Investors like Next47
• Investors like IVP
• Ribon Therapeutics

Bristol Myers Squibb alternatives · All research reports